None of the glycogenoses are currently detected by standard or extended newborn screening. The disease is more common in people of Ashkenazi Jewish, Mexican, Chinese, and Japanese descent. References
Further reading
GeneReview/NIH/UW entry on Glycogen Storage Disease Type I

External links
 Media related to Glycogen storage disease type I at Wikimedia Commons
Toxicity is associated to both dose and duration of treatment. Hence the use of (S,S)-enantiomer greatly improved the risk/benefit balance. Medical uses
Ethambutol is used along with other medications to treat a number of infections including: tuberculosis, Mycobacterium avium complex, and Mycobacterium kansasii. Adverse effects
Optic neuritis (hence contraindicated in children below six years of age)
Red-green color blindness People taking ethambutol should be monitored for changes in visual acuity and color discrimination. Arthralgia
Hyperuricaemia
Vertical nystagmus
Milk skin reaction

Mechanism of action
Ethambutol is bacteriostatic against actively growing TB bacilli. It works by obstructing the formation of cell wall. Mycolic acids attach to the 5-hydroxyl groups of D-arabinose residues of arabinogalactan and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. It disrupts arabinogalactan synthesis by inhibiting the enzyme arabinosyl transferase. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall. Pharmacokinetics
It is well absorbed from the gastrointestinal tract and well distributed in body tissues and fluids. 50% is excreted unchanged in urine. See also
chiral drugs
chirality
enantiopure drug
stereochemistry

References
External links
"Ethambutol". Medicine Plus. "Ethambutol". Drug Information Portal. U.S. National Library of Medicine.